Today: 20 March 2026
Browse Category

NASDAQ:GP 9 December 2025 - 15 January 2026

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

Wave Life Sciences shares jumped about 147% Monday after positive data on its experimental RNA obesity drug, leading US stock gainers. The Dow fell 0.45%, S&P 500 lost 0.35%, and Nasdaq slipped 0.14% as investors awaited Wednesday’s Federal Reserve decision. Nvidia rose after the US allowed exports of its H200 AI chips to China with a 25% fee.

Stock Market Today

  • Hecla Mining Boosts Cash Strength and Shareholder Returns Amid Strong Financial Discipline
    March 20, 2026, 1:27 PM EDT. Hecla Mining Company (HL) harnessed robust operating cash flow of $563 million in 2025, strengthening its balance sheet with net debt reduced to $34 million. The company paid $10.3 million in dividends, increasing its Q4 payout by 1.7% year-over-year, signaling a measured, shareholder-focused approach. With a net leverage ratio sharply down to 0.1x from 1.6x, HL maintains financial discipline to weather commodity volatility. Its free cash flow rose to $310 million, supporting both shareholder returns and growing exploration budgets. Compared to peers like Pan American Silver and First Majestic Silver, Hecla's shares surged 205.8% over the past year, outperforming the industry. However, HL trades at a higher forward price-to-earnings ratio of 28.65X versus the sector average of 14.63X and holds a Zacks Rank #3 (Hold), indicating cautious optimism about its future earnings growth and valuation.
Go toTop